Navigation Links
DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group

QUEBEC CITY, July 2 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Dr. Timothy J. Holzer, Vice President, R&D and Production at DiagnoCure, and Dr. Scott Waldman, from Thomas Jefferson University, were speakers on June 29, 2008, in Boston, Massachusetts, in a session at the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organizations in the United States. Dr. Holzer and Dr. Waldman discussed with members of the GI (gastro-intestinal) committee about the importance of DiagnoCure's GCC mRNA molecular marker in the staging of colorectal cancer.

Dr. Holzer presented research data on "Molecular Detection of Colorectal Cancer Lymph Node Micrometastasis". His presentation featured a statistical review and discussion of the beneficial role of GCC in the staging of colorectal cancer. Dr. Waldman discussed his discovery and recently completed clinical studies about the significant staging role of GCC in colorectal cancer in a talk entitled "Molecular Approaches to Individualized Management of Cancer".

GCC is expressed only in intestinal mucosal cells, but not in extra-intestinal tissues. In addition, GCC is expressed in colorectal tumors, but not in other cancers outside the gastro-intestinal tract. Therefore, GCC may be useful clinically for the management of patients with colorectal cancer in providing more accurate information about lymph node metastasis to physicians and patients and influencing treatment decisions.

About Previstage(TM) GCC

Staging a patient with colorectal cancer is crucial because it determines the patient's course of treatment. Current standard of care requires that pathologists examine microscopically a thin slice of tissue from each of 12 or more lymph nodes harvested during the patient's surgery to see if cancer has spread beyond the intestine. Currently up to 25 - 30 percent of patients with no histopathologically-positive lymph nodes (stage I and II cancers) later return with recurrent disease, presumably through occult metastases that have escaped detection. Most of these patients do not receive additional treatment such as chemotherapy. Previstage(TM) GCC aims to provide clinicians with a significantly more sensitive tool for staging a patient with colorectal cancer.

Clinical data from a 5-year prospective clinical study supported the potential importance of the GCC test in improving the staging of colorectal cancer patients. This study was sponsored by the National Cancer Institute. The study has been completed and the Company's collaborators at Thomas Jefferson University will be presenting the results of the study at major medical conferences later this year.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. In 2003, the Company entered into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation test for PCA3, DiagnoCure's proprietary molecular marker highly specific to prostate cancer. The test is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit

Forward-looking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
2. Elevated biomarkers predict risk for prostate cancer recurrence
3. Pancreatic Cancer Biomarkers Found
4. MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease
5. Celebrex May Reduce Levels of Lung Cancer Biomarker
6. USC researchers identify genetic markers that predict efficacy of novel cancer drug
7. New prognostic markers for gastric cancer patients
8. Biomarkers Predict Heart Deaths
9. Doctors Discover Marker for Meconium Passage During Delivery
10. Biomarker Spots Which Lesions Likely to Progress to Prostate Cancer
11. Monoclonal antibody Hb3: A marker for colon cancer progression or as a therapeutic target?
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, MTI-GlobalStem, a provider of optimized ... difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing ... is a complete system for culturing and transfecting human pluripotent stem cells ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology: